Self-Start Triage Model for Overactive Bladder

This trial examines the best ways to manage urinary tract infections (UTIs) in individuals receiving Botox® for overactive bladder. The study compares two approaches: one where patients receive a take-home prescription to start treatment if they suspect a UTI, and another where they must first contact a healthcare provider. The goal is to determine if the self-start method reduces urgent healthcare visits. Suitable candidates for this trial have an overactive bladder, are scheduled for Botox® treatment, and have access to email and MyChart for communication with healthcare providers. As an Early Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking insights.

The trial information does not specify whether you need to stop taking your current medications. However, if you are currently on prophylactic antibiotics, you would not be eligible to participate.

Research has shown that Nitrofurantoin, the main treatment in this trial, is generally safe for treating urinary tract infections (UTIs). Studies have found it effective for many sudden urinary infections, with most patients tolerating it well.

Nitrofurantoin may cause minor side effects like nausea or headache, but these are usually manageable. Importantly, long-term use of Nitrofurantoin carries a low risk of serious side effects or antibiotic resistance.

Researchers are excited about the Self-Start Triage Model for overactive bladder because it offers a proactive approach to managing urinary tract infections (UTIs). Unlike standard care, which requires patients to contact healthcare providers or visit clinics when symptoms appear, this model empowers patients to start treatment immediately with a standing prescription for Nitrofurantoin or other suitable antibiotics. This method could significantly reduce the time to treatment, potentially improving patient outcomes and reducing the burden on healthcare systems. By allowing patients to self-initiate treatment, this approach may streamline care and offer more timely relief from symptoms.

In this trial, participants in one arm will receive a standing prescription for Nitrofurantoin, commonly known as Macrobid, as part of a self-start triage model for overactive bladder. Research has shown that Nitrofurantoin effectively treats urinary tract infections (UTIs). One study found that 70% of women taking Nitrofurantoin experienced complete relief from UTI symptoms, compared to 58% who used a different antibiotic. A review of 12 studies confirmed that Nitrofurantoin is as effective as other long-term antibiotics in preventing recurring UTIs. It is often preferred over antibiotics like Ciprofloxacin for simple UTIs due to its safety profile, low risk of side effects, and minimal potential for developing antibiotic resistance.¹⁶⁷⁸⁹